Long-term non-invasive ventilation for COPD patients following an exacerbation with acute hypercapnic respiratory failure: a randomized controlled trial

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Long-term non-invasive ventilation for COPD patients following an exacerbation with acute hypercapnic respiratory failure : a randomized controlled trial. / Hedsund, Caroline; Linde Ankjærgaard, Kasper; Peick Sonne, Tine; Tønnesen, Philip; Frausing Hansen, Ejvind; Frost Andreassen, Helle; Berg, Ronan M.G.; Jensen, Jens Ulrik Stæhr; Wilcke, Jon Torgny.

In: European Clinical Respiratory Journal, Vol. 10, No. 1, 2257993, 2023.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Hedsund, C, Linde Ankjærgaard, K, Peick Sonne, T, Tønnesen, P, Frausing Hansen, E, Frost Andreassen, H, Berg, RMG, Jensen, JUS & Wilcke, JT 2023, 'Long-term non-invasive ventilation for COPD patients following an exacerbation with acute hypercapnic respiratory failure: a randomized controlled trial', European Clinical Respiratory Journal, vol. 10, no. 1, 2257993. https://doi.org/10.1080/20018525.2023.2257993

APA

Hedsund, C., Linde Ankjærgaard, K., Peick Sonne, T., Tønnesen, P., Frausing Hansen, E., Frost Andreassen, H., Berg, R. M. G., Jensen, J. U. S., & Wilcke, J. T. (2023). Long-term non-invasive ventilation for COPD patients following an exacerbation with acute hypercapnic respiratory failure: a randomized controlled trial. European Clinical Respiratory Journal, 10(1), [2257993]. https://doi.org/10.1080/20018525.2023.2257993

Vancouver

Hedsund C, Linde Ankjærgaard K, Peick Sonne T, Tønnesen P, Frausing Hansen E, Frost Andreassen H et al. Long-term non-invasive ventilation for COPD patients following an exacerbation with acute hypercapnic respiratory failure: a randomized controlled trial. European Clinical Respiratory Journal. 2023;10(1). 2257993. https://doi.org/10.1080/20018525.2023.2257993

Author

Hedsund, Caroline ; Linde Ankjærgaard, Kasper ; Peick Sonne, Tine ; Tønnesen, Philip ; Frausing Hansen, Ejvind ; Frost Andreassen, Helle ; Berg, Ronan M.G. ; Jensen, Jens Ulrik Stæhr ; Wilcke, Jon Torgny. / Long-term non-invasive ventilation for COPD patients following an exacerbation with acute hypercapnic respiratory failure : a randomized controlled trial. In: European Clinical Respiratory Journal. 2023 ; Vol. 10, No. 1.

Bibtex

@article{eab521607c6b4e63ae42fec978f0bd58,
title = "Long-term non-invasive ventilation for COPD patients following an exacerbation with acute hypercapnic respiratory failure: a randomized controlled trial",
abstract = "Introduction: It remains unclear whether long-term non-invasive ventilation (LT-NIV) for patients with chronic obstructive pulmonary disease (COPD) improves survival and reduces admissions as results from randomized trials are inconsistent. We aim to determine whether LT-NIV initiated after an admission with acute hypercapnic respiratory failure (AHRF) can affect survival and admission rate in COPD patients. Methods: A randomized controlled open-label trial, allocating patients with COPD to LT-NIV or standard of care immediately after an admission with AHRF treated with acute NIV. LT-NIV was aimed to normalize PaCO2 using high-pressure NIV. Results: The study was discontinued before full sample size due to slow recruitment. 28 patients were randomized to LT-NIV and 27 patients to standard of care. 42% of patients had a history of ≥ 2 admissions with AHRF. Median IPAP was 24 cmH2O (IQR 20–28). The primary outcome, time to readmission with AHRF or death within 12 months, did not reach significance, hazard ratio 0.53 (95% CI 0.25–1.12) p = 0.097. In a competing risk analysis, adjusted for history of AHRF, the odds ratio for AHRF within 12 months was 0.30 (95% CI 0.11–0.87) p = 0.024. The LT-NIV group had less exacerbations (median 1 (0–1) vs 2 (1–4) p = 0.021) and readmissions with AHRF (median 0 (0–1) vs 1 (0–1) p = 0.016). Conclusion: The risk of the primary outcome, time to readmission with AHRF or death within 12 months was numerically smaller in the LT-NIV group, however, did not reach significance. Nevertheless, several secondary outcome analyses like risk of AHRF, number of episodes of AHRF and exacerbations were all significantly reduced in favour of high-pressure LT-NIV, especially in patients with frequent AHRF.",
keywords = "Chronic obstructive pulmonary disease, non-invasive ventilation, respiratory failure",
author = "Caroline Hedsund and {Linde Ankj{\ae}rgaard}, Kasper and {Peick Sonne}, Tine and Philip T{\o}nnesen and {Frausing Hansen}, Ejvind and {Frost Andreassen}, Helle and Berg, {Ronan M.G.} and Jensen, {Jens Ulrik St{\ae}hr} and Wilcke, {Jon Torgny}",
note = "Publisher Copyright: {\textcopyright} 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",
year = "2023",
doi = "10.1080/20018525.2023.2257993",
language = "English",
volume = "10",
journal = "European Clinical Respiratory Journal",
issn = "2001-8525",
publisher = "Co-Action Publishing",
number = "1",

}

RIS

TY - JOUR

T1 - Long-term non-invasive ventilation for COPD patients following an exacerbation with acute hypercapnic respiratory failure

T2 - a randomized controlled trial

AU - Hedsund, Caroline

AU - Linde Ankjærgaard, Kasper

AU - Peick Sonne, Tine

AU - Tønnesen, Philip

AU - Frausing Hansen, Ejvind

AU - Frost Andreassen, Helle

AU - Berg, Ronan M.G.

AU - Jensen, Jens Ulrik Stæhr

AU - Wilcke, Jon Torgny

N1 - Publisher Copyright: © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

PY - 2023

Y1 - 2023

N2 - Introduction: It remains unclear whether long-term non-invasive ventilation (LT-NIV) for patients with chronic obstructive pulmonary disease (COPD) improves survival and reduces admissions as results from randomized trials are inconsistent. We aim to determine whether LT-NIV initiated after an admission with acute hypercapnic respiratory failure (AHRF) can affect survival and admission rate in COPD patients. Methods: A randomized controlled open-label trial, allocating patients with COPD to LT-NIV or standard of care immediately after an admission with AHRF treated with acute NIV. LT-NIV was aimed to normalize PaCO2 using high-pressure NIV. Results: The study was discontinued before full sample size due to slow recruitment. 28 patients were randomized to LT-NIV and 27 patients to standard of care. 42% of patients had a history of ≥ 2 admissions with AHRF. Median IPAP was 24 cmH2O (IQR 20–28). The primary outcome, time to readmission with AHRF or death within 12 months, did not reach significance, hazard ratio 0.53 (95% CI 0.25–1.12) p = 0.097. In a competing risk analysis, adjusted for history of AHRF, the odds ratio for AHRF within 12 months was 0.30 (95% CI 0.11–0.87) p = 0.024. The LT-NIV group had less exacerbations (median 1 (0–1) vs 2 (1–4) p = 0.021) and readmissions with AHRF (median 0 (0–1) vs 1 (0–1) p = 0.016). Conclusion: The risk of the primary outcome, time to readmission with AHRF or death within 12 months was numerically smaller in the LT-NIV group, however, did not reach significance. Nevertheless, several secondary outcome analyses like risk of AHRF, number of episodes of AHRF and exacerbations were all significantly reduced in favour of high-pressure LT-NIV, especially in patients with frequent AHRF.

AB - Introduction: It remains unclear whether long-term non-invasive ventilation (LT-NIV) for patients with chronic obstructive pulmonary disease (COPD) improves survival and reduces admissions as results from randomized trials are inconsistent. We aim to determine whether LT-NIV initiated after an admission with acute hypercapnic respiratory failure (AHRF) can affect survival and admission rate in COPD patients. Methods: A randomized controlled open-label trial, allocating patients with COPD to LT-NIV or standard of care immediately after an admission with AHRF treated with acute NIV. LT-NIV was aimed to normalize PaCO2 using high-pressure NIV. Results: The study was discontinued before full sample size due to slow recruitment. 28 patients were randomized to LT-NIV and 27 patients to standard of care. 42% of patients had a history of ≥ 2 admissions with AHRF. Median IPAP was 24 cmH2O (IQR 20–28). The primary outcome, time to readmission with AHRF or death within 12 months, did not reach significance, hazard ratio 0.53 (95% CI 0.25–1.12) p = 0.097. In a competing risk analysis, adjusted for history of AHRF, the odds ratio for AHRF within 12 months was 0.30 (95% CI 0.11–0.87) p = 0.024. The LT-NIV group had less exacerbations (median 1 (0–1) vs 2 (1–4) p = 0.021) and readmissions with AHRF (median 0 (0–1) vs 1 (0–1) p = 0.016). Conclusion: The risk of the primary outcome, time to readmission with AHRF or death within 12 months was numerically smaller in the LT-NIV group, however, did not reach significance. Nevertheless, several secondary outcome analyses like risk of AHRF, number of episodes of AHRF and exacerbations were all significantly reduced in favour of high-pressure LT-NIV, especially in patients with frequent AHRF.

KW - Chronic obstructive pulmonary disease

KW - non-invasive ventilation

KW - respiratory failure

UR - http://www.scopus.com/inward/record.url?scp=85171838493&partnerID=8YFLogxK

U2 - 10.1080/20018525.2023.2257993

DO - 10.1080/20018525.2023.2257993

M3 - Journal article

C2 - 37746028

AN - SCOPUS:85171838493

VL - 10

JO - European Clinical Respiratory Journal

JF - European Clinical Respiratory Journal

SN - 2001-8525

IS - 1

M1 - 2257993

ER -

ID: 370490509